Skip to main content

Advertisement

Table 1 Baseline characteristics of rheumatoid arthritis patients by response to anti-TNF therapy at 6 months

From: Variations in the metabolome in response to disease activity of rheumatoid arthritis

  Good responders (n = 100) Non-responders (n = 40) P-value
Age, years (mean ± SD) 50 ± 14 57 ± 13 0.44
Female (%) 76 (76) 31 (77.5) 1.00
Disease duration (months, range) 9 (3.3–15.3) 10 (3.7–12.8) 0.54
Infliximab (%) 13 (13) 7 (17) 0.64
Adalimumab (%) 29 (29) 17 (43) 0.32
Etanercept (%) 58 (58) 16 (40) 0.82
DAS-28 M0 (Mean ± SD) 4.8 ± 0.9 5.0 ± 1.2 -
DAS-28 M6 (Mean ± SD) 2.2 ± 0.6 4.8 ± 1.2 -
RF positivity (%) 77.4 70 0.25
ACPA positivity (%) 75 62 0.18
ERS (mm/h) 32 ± 25 35 ± 23 0.37
CRP (mg/l) 17 ± 19 21 ± 18 0.45
Bone erosion (%) 38 31 0.37
  1. RF rheumatoid factor, ACPA anticitrullinated protein antibodies, ERS erythrocyte sedimentation rate, CRP C-reactive protein